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ABSTRACT: To better understand the molecular mecha-
nisms underpinning physiological variation in human
populations, metabolic phenotyping approaches are increas-
ingly being applied to studies involving hundreds and
thousands of bioﬂuid samples. Hyphenated ultra-performance
liquid chromatography−mass spectrometry (UPLC-MS) has
become a fundamental tool for this purpose. However, the
seemingly inevitable need to analyze large studies in multiple
analytical batches for UPLC-MS analysis poses a challenge to
data quality which has been recognized in the ﬁeld. Herein, we
describe in detail a ﬁt-for-purpose UPLC-MS platform,
method set, and sample analysis workﬂow, capable of sustained
analysis on an industrial scale and allowing batch-free
operation for large studies. Using complementary reversed-phase chromatography (RPC) and hydrophilic interaction liquid
chromatography (HILIC) together with high resolution orthogonal acceleration time-of-ﬂight mass spectrometry (oaTOF-MS),
exceptional measurement precision is exempliﬁed with independent epidemiological sample sets of approximately 650 and 1000
participant samples. Evaluation of molecular reference targets in repeated injections of pooled quality control (QC) samples
distributed throughout each experiment demonstrates a mean retention time relative standard deviation (RSD) of <0.3% across
all assays in both studies and a mean peak area RSD of <15% in the raw data. To more globally assess the quality of the proﬁling
data, untargeted feature extraction was performed followed by data ﬁltration according to feature intensity response to QC
sample dilution. Analysis of the remaining features within the repeated QC sample measurements demonstrated median peak
area RSD values of <20% for the RPC assays and <25% for the HILIC assays. These values represent the quality of the raw data,
as no normalization or feature-speciﬁc intensity correction was applied. While the data in each experiment was acquired in a
single continuous batch, instances of minor time-dependent intensity drift were observed, highlighting the utility of data
correction techniques despite reducing the dependency on them for generating high quality data. These results demonstrate that
the platform and methodology presented herein is ﬁt-for-use in large scale metabolic phenotyping studies, challenging the
assertion that such screening is inherently limited by batch eﬀects. Details of the pipeline used to generate high quality raw data
and mitigate the need for batch correction are provided.
The measurement of low molecular weight metabolites inbioﬂuids is a fundamental tool for understanding human
physiological phenotypic variation1 and has wide application in
Received: April 15, 2016
Accepted: August 1, 2016
Published: August 1, 2016
Article
pubs.acs.org/ac
© 2016 American Chemical Society 9004 DOI: 10.1021/acs.analchem.6b01481
Anal. Chem. 2016, 88, 9004−9013
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
molecular epidemiology and personalized healthcare.2 The ﬁeld
has been propelled by advances in the analytical technology and
data processing methods required to capture and interpret data
derived from the metabolic pathways of complex biochemical
systems.3,4 Metabolic proﬁling, unlike conventional clinical
chemistry analyses, is not intended to be selective and therefore
generates simultaneous measurement of both expected and
potentially uncharacterized metabolites, making the approach
particularly fruitful in biomarker discovery.5 Multiplatform
proﬁling approaches are essential in the pursuit of achieving
comprehensive analytical coverage of the human metabolic
phenome, including supra-organismal metabolites from human
and associated gut microbial action on nutrients, xenobiotics,
and environmental contaminants.6
Metabolic proﬁles reﬂect human individuality,7,8 and
phenotypic variation is linked to complex interactions of a
person’s genetically coded metabolic machinery with their
environment.9−11 Despite this metabolic individuality, the
resulting phenotypes show similarities among groups of people
with common genetic or environmental (e.g., dietary, gut
microbiome) backgrounds when observed en masse.2,12 In
recent years, this study of phenotypic variation has taken the
form of molecular epidemiology, whereby metabolic bio-
markers of disease risk are sought via analysis of bioﬂuids,
typically urine and blood products, from large cohorts of
samples such as those derived from biobanks. Application of
statistical approaches, in particular metabolome-wide associa-
tion studies (MWAS),2,13,14 have been useful in elucidating
subtle metabolic signatures of disease and disease risk because
of the statistical power aﬀorded by population-level sample
collection and analysis.15,16 When paired with broad metabolite
proﬁling, these large-scale analyses are able to generate
unprecedented power in phenotypic comparisons of popula-
tions.13 The demand for bioﬂuid proﬁling in biobanking and
other large scale applications is therefore increasing rapidly.
Consequently, there is a fundamental requirement for high
precision analytical data generation for the most widely
sampled bioﬂuids. Nuclear magnetic resonance (NMR) spec-
troscopy has long been a favored analytical platform for the
generation of metabolic proﬁles with quantitative values and
high reproducibility facilitating comparisons among individuals
or groups of individuals within populations.17−20 Nevertheless,
the technique is limited when used for rapid proﬁling both in
terms of its ability to discern individual molecules in complex
mixtures and its sensitivity. Liquid chromatography coupled to
mass spectrometry (LC-MS) oﬀers a complementary approach
for bioﬂuid analysis, boasting multidimensional high resolution
separations and sensitive detection across a broad range of
chemical species.21,22 However, exploratory LC-MS platforms
can suﬀer from batch variations, run order eﬀects, and lack of
reproducibility, due in part to the complexity of the hyphenated
system involving the distinct processes of high pressure liquid
separation followed by analyte ionization and ﬁnally mass
spectrometric separation and detection. High coeﬃcients of
variation from LC-MS measurements have been observed when
attempting analysis of samples from large patient cohorts23
indicating the diﬃculty in achieving stable metabolic signatures
in large-scale analysis. Despite this, the allure of epidemio-
logical-scale metabolic data sets continues to drive the
development of LC-MS approaches for large-scale bioﬂuid
characterization24,25 as well as the development of informatic
approaches22,26−30 to combat seemingly inevitable24,31,32
analytical imprecision (e.g., sample batch eﬀects).
Both blood products (i.e., plasma and serum) and urine are
commonly collected and available in biobanks for molecular
epidemiology studies. While the analysis of blood products has
been the subject of recent advances ﬁt for the purpose of large-
scale application,22 the ultra-performance liquid chromatog-
raphy−mass spectrometry (UPLC-MS) approaches used for
analysis of human urine have not been suﬃciently demon-
strated for this purpose. Here, we report the adaptation of
UPLC and orthogonal acceleration time-of-ﬂight mass
spectrometry (oaTOF-MS) systems for urine analysis, deliver-
ing a platform capable of continuous operation which
minimizes the need for collection of data in distinct batches,
maximizes eﬃciency, and produces high quality data with high
analytical precision. Complementary reversed-phase chroma-
tography (RPC) and hydrophilic interaction liquid chromatog-
raphy (HILIC) separations coupled to oaTOF-MS are
individually the most common LC-MS techniques used for
metabolic phenotyping of urine31 and were developed here for
high precision chromatographic separation within a window of
time deﬁned by the practical constraints imposed by a high
throughput working laboratory. The achievable degree of
reproducibility is exempliﬁed using two independent sets of
human urine samples from distinct large-scale epidemiological
studies: the Alzheimer’s Disease Multimodal Biomarkers study
(ALZ)33,34 and the Airwave Health Monitoring study (AW) of
police oﬃcers and staﬀ in Great Britain.35
■ EXPERIMENTAL SECTION
Since quality control (QC) is essential to the development and
demonstration of this protocol, multiple reference materials
were developed and used to monitor and evaluate data quality.
Details of the chemical composition and sources of the method
reference (MR) and internal standards (IS) chemical mixtures,
study reference (SR) and long-term reference (LTR) pooled
urine samples, sample preparation, and data acquisition
procedures and parameters are contained within the Supporting
Information. Key aspects of chromatographic and UPLC-MS
system adaptation and control are described here.
Sample Preparation and Method Timing Consider-
ations. The 96-well plate format is a standard utilized in many
high throughput/high volume processes including cell screen-
ing, PCR ampliﬁcation, and immunoassays (e.g., ELISA) and
was therefore adopted as the fundamental block unit for
bioﬂuid sample preparation. To establish a regular period for
preparation and analysis of sample plates, an analytical cycle of
exactly 15 min was selected which allowed the analysis of a
single block of 96 samples in 24 h. Further blocks may then be
appended at convenient and regular intervals to facilitate
continuous analysis.
UPLC-MS System Conﬁguration. All UPLC-MS systems
used herein for development and sample analysis utilized the
following three components. The sample handling component
was a Waters 2777C sample manager (Waters Corp., Milford,
MA, USA) equipped with a 25 μL Hamilton syringe, a 2 μL
loop used for full-loop injections of prepared sample, and a 3-
drawer sample chamber thermo-stated at 4 °C with a constant
ﬂow of dry nitrogen gas to prevent the buildup of condensation.
The LC component was an ACQUITY UPLC (Waters Corp.,
Milford, MA, USA) composed of a binary solvent manager and
column heater/cooler module. Finally, the MS component was
a Xevo G2-S oaTOF MS (Waters Corp., Manchester, UK)
coupled to the UPLC via a Zspray electrospray ionization (ESI)
source.
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Reversed-Phase Chromatography (RPC) Method De-
velopment. The stationary phase and mobile phase conditions
previously reported by Wong et al.36 were adopted for use in
bioﬂuid proﬁling due to their established suitability for the
retention of small polar species in highly aqueous environments
and separation of less polar species over the course of a gradient
elution.21 Water and acetonitrile, each supplemented with 0.1%
formic acid (mobile phases A and B, respectively), were chosen
for the mobile phase because of their ease of volumetric
preparation or direct commercial availability in large batches,
mitigating concern for solvent preparation as a cause for batch
eﬀects. A 2.1 × 150 mm HSS T3 column thermostatted at 45
°C was used with a mobile phase ﬂow rate of 0.6 mL/min,
generating a maximum pressure of approximately 12 000 psi
(80% of the maximum achievable system pressure of 15 000
psi) in a water/acetonitrile gradient. The chosen ﬂow rate
represents a balance between chromatographic performance
(maximized in UPLC at high mobile phase linear velocities37)
and observed MS intensity which is concentration sensitive and
therefore inversely related to eﬄuent ﬂow rate.38,39 The ﬂow
rate was well tolerated by the ESI source, even when the
eﬄuent was highly aqueous.
After a 0.1 min isocratic separation at initial conditions (99%
A), a linear gradient elution (99% A to 45% A in 9.9 min) was
applied, generating the data-rich portion of the separation,
followed by a more rapid gradient (45% A to 0% A in 0.7 min)
to ﬁnal conditions. In the latter stage, the mobile phase ﬂow
rate was simultaneously increased to 1.0 mL/min, allowing
faster column washing. Due to the relatively low viscosity and
high volatility of the organic component of the mobile phase,
no problems with LC system pressure or desolvation in the MS
interface were observed during increased ﬂow conditions.
Changes in ﬂow rate were applied gradually in order to utilize
available system pressure without introducing large ﬂuctuations.
The duration of column equilibration was adjusted to provide
suﬃcient retention and chromatographic precision of early
eluting species in subsequent analyses at the minimal expense
of time. The ﬁnal gradient conditions for the RPC separation
are summarized in Table SI-1, and an accompanying
representative LC system pressure trace is provided in Figure
SI-1.
Hydrophilic Interaction Liquid Chromatography
(HILIC) Method Development. The chromatographic
retention and separation of small polar molecules was
conducted using a 2.1 × 150 mm Acquity BEH HILIC column
(Waters Corp., Milford, MA, USA) thermostatted at 40 °C.
The solvent system chosen was acetonitrile with 0.1% formic
acid (A) and 20 mM ammonium formate in water with 0.1%
formic acid (B). The ﬂow rate of 0.6 mL/min established for
the RPC separation was found to be equally well suited for
application in the HILIC separation and was therefore used
during sample loading and gradient elution. After a 0.1 min
isocratic separation at initial conditions (95% A), a two-stage
gradient was conducted to achieve approximately uniform peak
shape in the elution of urinary analytes. First, a shallow linear
gradient between 95% and 80% A was used followed by a more
rapid gradient from 80% to 50% A in order to improve the peak
shape of late eluting analyte species which otherwise appeared
as broad and sometimes tailing peaks. Following a return to
initial composition, the ﬂow rate was increased to 1.0 mL/min
to expedite equilibration of the chromatographic system,
providing suﬃcient retention and chromatographic precision
of early eluting species in subsequent analyses. The ﬁnal
gradient conditions for the HILIC separation are summarized
in Table SI-2, and an accompanying representative LC system
pressure trace is provided in Figure SI-2.
As HILIC methods are often reported to beneﬁt from longer
equilibration times relative to RPC,31,40−42 the method herein
was speciﬁcally designed to allow for extended equilibration
without precluding the option for increased throughput. This
was accomplished by ensuring the complete elution of analytes
by 7.5 min (half of the total run time), making the method
compatible with specialized chromatographic systems capable
of column switching, mating two independent separations to a
single mass spectrometer in staggered parallel operation. While
capable of doubling the productivity of a single mass
spectrometer, such a system was not implemented in the
studies reported here.
Optimization of UPLC-MS System Conﬁguration. The
ESI source used to couple the UPLC to the MS allowed for
adjustable angular positioning of the sample probe in relation to
the inlet cone. The potential for accumulation of sample-
derived residue on the inlet cone and guard was minimized by
using the most orthogonal setting that still allowed for a near-
maximum signal detected for reference standards within the
RPC MR mixture. A setting of 7 mm on the adjustment
micrometer was used for all assays. To further protect the cone
from residue accumulation during operation, the cone gas ﬂow
was set to 150 L/h, representing the highest ﬂow achievable
while maintaining near maximal signal intensity for RPC MR
standards. Optimized ion source and ion guide settings were
established to maximize the observed signal and minimize
fragmentation of small molecules using the standards within the
RPC MR. These probe position, source, and ion guide settings
were standardized for use within the laboratory for all assay
types applicable to urine analysis. Furthermore, as standard
practice, each instrument was tuned to achieve high resolution
at maximum sensitivity immediately prior to conducting each
assay (see the Supporting Information for details of tuning
procedure and resolution values achieved). RPC analysis was
performed in both positive and negative ion modes (RPC+ and
RPC−, respectively) while the HILIC assay was performed in
the positive ion mode only (HILIC+). Instrument-speciﬁc
details are provided in the Supporting Information.
MS Detector Gain Control. A prototype software
algorithm was developed to maintain consistent electron
multiplier gain during sustained use. During instrument setup,
the applied detector voltage was adjusted to give an optimum
signal-to-noise ratio for digitized signals arising from individual
ion arrivals, ensuring eﬃcient recording of the majority of ion
arrivals. The relative detector gain was measured at this
optimum voltage, establishing the target value to be maintained
throughout the series of sample analyses. This value was
determined by calculating the ratio of summed intensities
between mass spectral data digitized using an analogue-to-
digital converter and mass spectral data acquired in an ion
counting mode of operation. This ratio provides a measure of
the mean area of the signal arising from ion arrivals over a given
mass-to-charge ratio (m/z) range after digitization and
ampliﬁcation. To compensate for a loss of gain observed
under sustained operation, the algorithm automatically adjusts
the applied detector voltage in response to relative gain
measurements taken immediately prior to each new sample
injection. By interpolating between the current relative detector
gain value and the value measured after an arbitrary increase in
detector voltage (+25 V), a new detector voltage value may be
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calculated prior to each injection such that the relative gain is
maintained at the reference value throughout the analysis.
The overall gain of an electron multiplier, under constant
operating conditions, is dependent on ion velocity and hence
on the m/z of the incident ions. Therefore, measuring relative
gain over a wide mass range gives a value dependent on the
relative population of ions at each m/z value. With this in mind,
the chemical noise arising from ionization of LC eﬄuent during
chromatographic equilibration was used as a stable and
reproducible signal when performing gain measurements.
This method negates the requirement for separate introduction
of a reference sample, providing highly reproducible spectra
while avoiding the need for eﬄuent diversion during measure-
ment. In order to maintain a regular analytical cycle and to
avoid variation in column equilibration times between sample
injections (potentially detracting from analytical reproduci-
bility), the algorithm was designed to run for a ﬁxed time of 2
min, regardless of (typically in excess of) the time required to
complete calculation and adjustment. This time corresponds to
the column equilibration period, and therefore, this function-
ality did not extend the overall experiment time.
Human Population Studies for Method Exempliﬁca-
tion. The methods and UPLC-MS system conﬁguration
described herein were applied to selected sample sets from
two independent epidemiological studies in order to exemplify
the quality of data produced across distinct experiments. The
ﬁrst set (ALZ) was derived from a UK epidemiological study of
Alzheimer’s disease and conversion from mild cognitive
impairment. Urine samples were collected from Alzheimer’s
disease patients (n = 200), participants with mild cognitive
impairment (n = 575), and control participants (n = 200). A
subset of these samples (n = 655) was provided for molecular
phenotyping by both HILIC and RPC methods. All samples
remained unaliquoted and frozen (never thawed) at −80 °C for
an average duration of approximately three years (range = 1 to
10 years) following collection. The second set (AW) was
derived from an epidemiological study of microwave radiation
exposure from terrestrial trunked radio (TETRA) use by police
personnel within the UK. Samples from 1040 (RPC) and 1000
(HILIC) participants were selected for use in this study. Urine
samples were collected within various clinics local to
participating UK police forces, aliquoted into 2 mL cryovials,
shipped to a central laboratory at 4 °C within 24 h, and then
placed at −80 °C and later at −180 °C in liquid nitrogen for
long-term storage. The maximum duration of storage was eight
years, and during this time, samples were never thawed. No
preservatives were added to the urine samples of either set.
Biological end points of the ALZ and AW studies were
considered to be outside the scope of analytical performance
assessment and are therefore not presented.
Feature Extraction, Data Filtration, and Quality
Assessment. For each study and each analysis type (RPC+,
RPC−, and HILIC+), the quality of the data set produced was
assessed using data extracted from the repeated regular
injections of SR and LTR urine samples, alternating every 5
study sample injections, supplemented with the chromato-
graphic method-appropriate RPC or HILIC MR mixture. This
approach enables the complementary evaluation of both
speciﬁc molecular targets and the aggregate of all detectable
small molecule features. Targeted detection and integration of
MR and IS analyte peaks were performed across all QC and
QC dilution series samples using TargetLynx (MassLynx 4.1)
and manually reviewed for accuracy. Untargeted peak detection,
alignment, grouping, integration, and deisotoping were
performed on each full data set (all study samples, QC
samples, and QC dilution series samples) using Progenesis QI
2.1 software (Waters Corp., Manchester, UK). Inclusion of the
study samples can potentially aﬀect the alignment and grouping
of features in untargeted feature extraction (versus performing
the procedure on the QC samples only), and therefore while
the study sample data were not used for the evaluation of
analytical precision, they were included in the preprocessing.
This was done in order to be consistent with the manner in
which a proﬁling data set would be processed for biological
interpretation. Parameters for both targeted and untargeted
feature detection procedures are provided in the Supporting
Information. Detected and integrated chromatographic peaks
belonging to the same spectral feature of the same chemical
species across all samples are referred to herein as “feature
groups”.
In an approach adapted from Croixmarie et al.,43 the
response of each feature group (extracted by both untargeted
and targeted means) to sample dilution was assessed by
calculation of Pearson correlation coeﬃcients between the QC
sample dilution factor and the extracted signal intensity for the
pre- and postsample analysis dilution series. The motivation for
this approach is to identify feature groups that are not
correlated to the gradient of concentration generated by the
dilutions series and therefore should not be considered as
reliable features. Thus, feature groups with correlation
coeﬃcient of less than 0.8 were removed from the data set.
The resulting data is presented without application of data
correction procedures (e.g., normalization or curve ﬁtting) in
order to facilitate clear reporting and evaluation of the data
quality produced by the optimized analytical platform.
■ RESULTS AND DICUSSION
Consideration of the Importance of a Regular
Analytical Cycle for Continuous Operation. The regularity
of analysis achieved using 96-well plates paired with a 15 min
analytical cycle grants eﬃciency to the measurement platform,
producing a dependable schedule of sample preparation and
analysis which can be easily managed to allow continuous
batch-free operation of large sample sets (ca. 1000 samples).
Such a cycle helps to avoid situations where variable numbers
of sample plates must be prepared and submitted to ensure
analysis does not stop outside of working hours. By avoiding
the need for reactive sample management, the variation in
sample age (between preparation and analysis) can be more
easily controlled, limiting time-dependent chemical changes as
a source of variance in the observed proﬁles. Therefore, cycle
times of 15 min (1 plate per day), 10 min (3 plates per 2 days),
7.5 min (2 plates per day), 5 min (3 plates per day), and so on
are advocated for ease of maintenance, allowing continuous
batch-free analysis. Here, a 15 min analytical cycle was selected
as providing both a generous amount of time for chromato-
graphic separation of the complex bioﬂuid sample and a
minimal range of sample ages.
Chromatographic Performance of RPC and HILIC
Methods. Working within the constraint of a 15 min analytical
cycle, RPC and HILIC methods were developed for separation
performance and precision. A special emphasis was placed on
resolution of early eluting species, using 150 mm columns in
both chromatographic modes to improve chromatographic
eﬃciency (relative to 100 or 50 mm lengths more traditionally
used for UPLC applications) in the earliest region of the urine
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chromatogram where the separation is occurring under virtually
isocratic conditions and feature density is high with small polar
analytes (particularly in RPC analyses). Base peak intensity
chromatograms of LTR sample analyses by each UPLC-MS
method (RPC+, RPC−, HILIC+) are shown in Figure 1,
illustrating the separation and distribution of analytes within
the urine matrix.
The retention time precision of each chromatographic
method was assessed using the MR standards and IS within
the QC samples of each study as exemplary molecular targets.
SR and LTR samples were assessed collectively, as retention
time is expected to be independent of matrix composition.
Feature-speciﬁc measurements across all 130 QC samples (ALZ
study, all assays) and 208/200 QC samples (AW study, RPC/
HILIC assays, respectively) are summarized in Table SI-3.
When considering these results, it is important to recall that
QC samples were spread evenly throughout 780 total sample
injections for the ALZ study and 1248/1200 injections for the
AW study (RPC± and HILIC+ analyses, respectively). The
retention time relative standard deviation (RSD) was less than
1% for all individual reference standards, and the mean RSD of
all method reference standards for each assay did not exceed
0.30%. These results were achieved despite the long duration of
the studies and the consequential need to regularly supplement
mobile phase buﬀer and solvent with freshly prepared or newly
opened stock. While the RPC method utilizes solvent
formulations that are directly commercially available and
obtainable from a single manufacturing batch, preparation of
HILIC solvents is typically more operator dependent due to
their tailored composition. Separation of the HILIC mobile
phase into unblended aqueous and organic components
(consistent with the recent work of Jacob et al.44 but deviating
from most other published HILIC implementations for urine
analysis21,31,45,46) and reliance on the UPLC hardware to
establish a precise initial mixture of organic solvent with a small
aqueous component (5%) resulted in a simple and repeatable
mobile phase preparation procedure, contributing to the high
degree of retention time precision observed.
Raw UPLC-MS Data Quality of Molecular Targets. The
quality of the raw UPLC-MS data was assessed by integrating
the extracted ion chromatogram (EIC) peak areas of the MR
and IS molecular targets and calculating their RSD values
within each QC sample type. These results are summarized in
Table 1.
Separate treatment of the SR and LTR samples is
representative of their potential use as independent control
and validation QC samples, the merits of which have been
discussed previously.29 Consistent precision was observed
between SR and LTR sample sets for each analysis type.
Within the RPC analyses, negative mode detection generally
produced slightly higher measurement variation than positive
mode detection. As the samples analyzed on each RPC system
were split aliquots from the same set of prepared samples, the
diﬀerence in assay performance appears to be a consequence of
either interinstrument variance or the mode of operation, the
latter being consistent with previous reports of positive mode
ESI-MS outperforming negative mode when using the same
chromatographic method.23,47 Nevertheless, the overall results
demonstrate a high degree of analytical precision within the raw
data across all assays and both independent large studies.
Feature Selection and Variance in UPLC-MS Proﬁling
Data. The feature-extracted data set produced by automatic
peak detection, grouping, and integration will invariably contain
noise from the analytical system (e.g., signals from mobile
phase chemical contaminants) as well as potential artifacts from
the feature extraction process. Depending on the parameters
used for feature extraction, such signals can amount to a
substantial portion of the total number of features detected and
Figure 1. Representative base peak intensity chromatograms of long-
term reference urine sample analyses by reversed phase chromatog-
raphy (RPC) or hydrophilic interaction liquid chromatography
(HILIC) with the indicated positive or negative ion mode mass
spectrometry (±).
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therefore may inﬂuence downstream data treatments such as
normalization and multivariate modeling. Simple noise ﬁltering
strategies such as the minimum fraction ﬁlter used within
XCMS target and remove infrequently observed signals within
distinct sample classes48,49 and are therefore not well suited to
large epidemiological studies of populations without distinct
subgroupings. We utilize an alternate strategy in which the
intensity of features must be correlated to the matrix
concentration in a series of diluted SR samples in order to be
retained for further analysis. This ﬁlter has no dependency on
the study design and is therefore applicable in both small
discriminant studies and large phenotyping eﬀorts. Beyond its
use as a system noise removal tool, the dilution series ﬁlter also
helps to ensure that the observed signal of a given feature and
its relative concentration in the sample are positively correlated,
beneﬁting the interpretation of proﬁling data. The eﬀects of
dilution series ﬁltration are shown using a representative feature
set (AW RPC+) as a selected example, illustrating the
distribution of eliminated and passing signals, including the
removal of chemical noise (Figure SI-3).
Table 1. Peak Area Precision of Reference Standards within the Alzheimer’s (ALZ) and AIRWAVE (AW) Studies for Reversed-
Phase Chromatography (RPC) and Hydrophilic Interaction Liquid Chromatography (HILIC) Analysesa
aResults are expressed in terms of relative standard deviation (RSD%), and measurements with variance greater than 15% RSD are highlighted in
blue. Diﬀerent labeled versions of taurine and creatine were utilized between the ALZ and AW studies (see the Supporting Information for details).
Figure 2. Relative standard deviation (RSD) values for all feature groups across all study reference (SR) samples (black), long-term reference (LTR)
samples (red), and study samples (blue) within the AW RPC+ data set. Feature groups are presented in rank order along the y-axis from lowest to
highest SR RSD. LTR sample RSD values are tightly clustered around the SR values demonstrating precision consistency between the independent
QC sample sets. Study sample RSD, representing the combination of analytical and biological variance, is scattered in a log-normal distribution and is
generally in excess of the analytical variance observed. The higher RSD values in study samples (relative to the QC sample sets) illustrate the
biological information contained within.
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Data sets may be further reﬁned by removal of feature groups
that do not meet an arbitrary threshold of peak area
measurement precision prior to downstream analysis. This
approach, utilizing RSD values derived from repeated measure-
ments of a pooled QC sample, is becoming increasingly
mainstream in molecular proﬁling literature.50 However, such
an approach fails to account for the relationship between the
observed analytical and total (including biological) variation in
each chemical species measured. Using the same selected
example data set (AW RPC+), the comparison of analytical and
total variance observed in the data set was assessed by
juxtaposition of the RSD values calculated for each feature
group within the SR, LTR, and study samples. The results are
shown in Figure 2 (results from AW RPC− and HILIC+ assays
are included as Figures SI-4 and SI-5, respectively). The
observed analytical variance is generally consistent between SR
and LTR sample measurements for each feature group, and for
the vast majority of features, the variance observed within the
study samples is greater than the variance observed within
either QC sample type. This gives conﬁdence that the study
sample measurements contain information potentially relevant
to phenotypic variation. For this selected case, the 30% RSD
threshold often adopted in the literature as a data ﬁlter does
appear to be sensible, albeit arbitrary, for eliminating feature
groups that do not demonstrate substantial variance in study
samples beyond that measured in the QC samples (indicating
low biologically relevant variation). However, elimination of
feature groups according to the ratio of observed variance
between the QC samples and study samples may ultimately
prove to be a more relevant criterion, allowing the RSD
threshold to be adaptive with respect to the degree of biological
variance implicit within each feature group. This approach is
therefore proposed here as an alternative to data ﬁltration based
on a static QC sample RSD value.
Raw UPLC-MS Quality of Global Proﬁling Data. To
complement the targeted assessment of data quality with a
more global interrogation of measurement precision, the
distribution of RSD values51 for all features passing the dilution
series ﬁlter was calculated for the SR samples. Figure 3
illustrates the distributions for each analytical method. For
visual clarity, the x-axes have been truncated at 80% RSD;
however, all data were incorporated in the calculation of quality
statistics. The data have also been subdivided on the basis of
the mean feature group intensity in SR samples, into the
bottom, top, and middle-two quartiles (shown in blue, red, and
green) to illustrate the relation between feature intensity and
precision. The median RSD values for the RPC+ method were
16.1% and 12.7% for the ALZ and AZ studies, respectively,
19.3% and 18.3% for the RPC− assay, and 21.4% and 24.3% for
the HILIC+ assay. It is notable that RPC remains the more
robust and dependable chromatographic method, justifying
eﬀorts at expanding its molecular coverage of small polar
molecules.
When considering these values in the greater context of
values reported in the literature for metabolic proﬁling of urine,
it is important to note that they diﬀer from other reports where
data correction, normalization, or selection is performed prior
to reporting data set quality.23,29,30,44,45,47,52−59 While these
approaches may be ﬁt for the purposes of comparing the
combined analytical and informatic precision of the ﬁnal data
sets for biological interpretation, they make direct comparison
of raw data quality diﬃcult. Nevertheless, viewed as a whole,
these results clearly illustrate a high degree of raw analytical
precision throughout the feature measurements among all
assays in two independent large studies, demonstrating the
quality of data generated by the analytical platform and
methods.
Figure 3. Relative standard deviation (RSD) distributions for feature groups passing dilution series ﬁltering as measured within the study reference
(SR) samples of each assay (RPC+, RPC−, and HILIC+) for both studies (ALZ and AW). The distributions are segmented by mean feature group
intensity into lower quartile (blue), interquartile range (green), and upper quartile (red). RSD values were calculated across all 104 SR samples (AW
RPC+ and RPC−), 99 SR samples (AW HILIC+), and 65 SR samples (ALZ RPC+, RPC−, and HILIC+).
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MS Detector Performance and Gain Control. Through-
out each experiment, automatic control of the voltage applied
to the MS detector was used to mitigate changes in detector
gain during sustained analysis. The mean change in applied
voltage was approximately 0.15 V per sample across all assays in
each experiment (an exemplar scatter plot of detector voltage
across an experiment is provided in Figure SI-6). In addition to
contributing to the precision in peak area described previously,
the stabilizing eﬀect of this adaptive control system helps to
maintain the fundamental ion detection eﬃciency of the
instrument, mitigating the potential drift and eventual loss of
low intensity signals below the limit of detection. This approach
is conceptually diﬀerent from data normalization or other
methods of correction which are applied after data acquisition
to correct for longitudinal trends in signal intensity, as the latter
cannot correct for changes in relative response with respect to
absolute signal intensity which arise from ineﬃcient ion
detection and they cannot restore lost signals. It is also
important to note that the magnitude of voltage adjustment
required per sample is calculated on background chemical noise
from the LC eﬄuent during column equilibration and is
therefore reliant neither on the composition or the
concentration of a speciﬁc analyte nor on the experimental
data itself.
Relevance of Data Reﬁnement Approaches. Reducing
dependency on data treatment procedures in order to elucidate
subtle eﬀects in large populations is a key aim in the
development of high precision analytical assays. Here, we
have demonstrated that achieving batch-free analysis is key in
producing high precision raw data, mitigating the need for
computationally intense data correction analytics and thereby
limiting the potential for overcorrection and artifact introduc-
tion. Nevertheless, the development of mathematical analytics
for correcting sample run-order and batch eﬀects remains
necessary and beneﬁcial to molecular proﬁling studies. While
the work presented herein demonstrates a high degree of raw
data quality achievable, it also conﬁrms the persistence of
analyte-speciﬁc longitudinal trends (drift) in such analyses.
A detailed investigation of the slightly increased variance
observed in the negative mode analysis (relative to positive
mode) indicated greater longitudinal trends in feature intensity
as the cause of the higher RSD values, rather than increased
random variance in measurement alone. Indeed, feature-speciﬁc
trends are commonly observed throughout the data sets
investigated here despite the high degree of overall precision.
The behavior of labeled L-leucine in the ALZ RPC- data set
(having the highest RSD value in the LTR samples) is
illustrated in Figure 4 as an exemplary case. Feature speciﬁc LC-
MS data correction procedures such as curve ﬁtting29 and
LOESS regression22 may be appropriately applied and expected
to perform well, further improving the data precision in a
feature-speciﬁc manner. To illustrate this in the selected
example, a simple cubic spline was ﬁtted to the SR samples
and interpolated to correct the independent LTR samples,
eliminating the longitudinal drift and reducing the measure-
ment RSD from 13.8% to 3.8% in the LTR samples (Figure 4).
Additionally, it is important to note that the analytical
continuity achieved here is subject to unexpected disturbance,
as hardware or software errors may still introduce batch eﬀects
into an otherwise high precision analysis. In these instances,
batch correction tools that produce high precision data sets
without erroneously constraining meaningful biological var-
iance remain valuable assets.
■ CONCLUSIONS
These results demonstrate the feasibility of collecting
exploratory UPLC-MS data suitable for the elucidation of
subtle metabolic eﬀects within epidemiological studies. The
system described is capable of continuous analysis, producing
data with exceptional precision when applied at a large scale.
Minimization of signal loss is pursued throughout the
development of the UPLC-MS platform conﬁguration and
assay set, maximizing sensitivity in order to eﬀectively trade it
for longitudinal stability. This is achieved in part by adjustment
of the MS ion optics and ion source parameters to maximize
sensitivity with commensurate minimization of sample material
injected. Together, these steps limit signal loss due to source
and ion optic contamination with biological matrix and
eliminate the need for related intervention and maintenance
(with consequential batch eﬀects) during large scale experi-
ments. Additional measurement stability is provided by
automatic MS detector gain control, adaptively compensating
for trends in instrument performance without reliance on the
experimental data. By mitigating signal loss end-to-end, the
UPLC-MS system becomes a robust platform for molecular
proﬁling of the imprinted metabolic processes observable in
human urine. Acquisition of high precision data reduces the
need for informatic correction but does not eliminate it entirely
as longitudinal trends and batches due to software/hardware
failure can still pose threats, highlighting system robustness as a
key factor in large scale phenotyping applications.
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